200 related articles for article (PubMed ID: 37753740)
21. The Role of Fibrinolytic System in Health and Disease.
Kwaan HC
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563651
[TBL] [Abstract][Full Text] [Related]
22. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Tang L; Han X
Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
[TBL] [Abstract][Full Text] [Related]
23. Detection of the plasmin system in human mammary pathology using immunofluorescence.
Clavel C; Chavanel G; Birembaut P
Cancer Res; 1986 Nov; 46(11):5743-7. PubMed ID: 2428483
[TBL] [Abstract][Full Text] [Related]
24. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Albo D; Rothman VL; Roberts DD; Tuszynski GP
Br J Cancer; 2000 Aug; 83(3):298-306. PubMed ID: 10917542
[TBL] [Abstract][Full Text] [Related]
25. Extracellular matrix degradation by cultured mesangial cells: mediators and modulators.
Baricos WH; Reed JC; Cortez SL
Exp Biol Med (Maywood); 2003 Oct; 228(9):1018-22. PubMed ID: 14530509
[TBL] [Abstract][Full Text] [Related]
26. Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells.
Ellis V; Whawell SA
Blood; 1997 Sep; 90(6):2312-22. PubMed ID: 9310482
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions.
Lobov S; Croucher DR; Saunders DN; Ranson M
Thromb Haemost; 2008 Aug; 100(2):319-29. PubMed ID: 18690354
[TBL] [Abstract][Full Text] [Related]
28. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen.
Andrade-Gordon P; Strickland S
Biochemistry; 1986 Jul; 25(14):4033-40. PubMed ID: 2943315
[TBL] [Abstract][Full Text] [Related]
29. Metabolite profiling reveals a connection between aldehyde dehydrogenase 1A3 and GABA metabolism in breast cancer metastasis.
Dahn ML; Walsh HR; Dean CA; Giacomantonio MA; Fernando W; Murphy JP; Walker OL; Wasson MD; Gujar S; Pinto DM; Marcato P
Metabolomics; 2022 Jan; 18(1):9. PubMed ID: 34989902
[TBL] [Abstract][Full Text] [Related]
30. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
[TBL] [Abstract][Full Text] [Related]
31. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
32. Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.
Albo D; Berger DH; Wang TN; Hu X; Rothman V; Tuszynski GP
Surgery; 1997 Aug; 122(2):493-9; discussion 499-500. PubMed ID: 9288157
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
34. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Dutta S; Bandyopadhyay C; Bottero V; Veettil MV; Wilson L; Pins MR; Johnson KE; Warshall C; Chandran B
Mol Oncol; 2014 May; 8(3):483-507. PubMed ID: 24457100
[TBL] [Abstract][Full Text] [Related]
35. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
36. Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells.
Chu EK; Cheng J; Foley JS; Mecham BH; Owen CA; Haley KJ; Mariani TJ; Kohane IS; Tschumperlin DJ; Drazen JM
Am J Respir Cell Mol Biol; 2006 Dec; 35(6):628-38. PubMed ID: 16794260
[TBL] [Abstract][Full Text] [Related]
37. Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin.
Silverstein RL; Harpel PC; Nachman RL
J Biol Chem; 1986 Jul; 261(21):9959-65. PubMed ID: 2942536
[TBL] [Abstract][Full Text] [Related]
38. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
[TBL] [Abstract][Full Text] [Related]
39. uPA-mediated plasminogen activation is enhanced by polyphosphate.
Whyte CS; Mutch NJ
Haematologica; 2021 Feb; 106(2):522-531. PubMed ID: 32029503
[TBL] [Abstract][Full Text] [Related]
40. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
